166 related articles for article (PubMed ID: 8635869)
21. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
[TBL] [Abstract][Full Text] [Related]
22. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
[TBL] [Abstract][Full Text] [Related]
23. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
24. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143
[TBL] [Abstract][Full Text] [Related]
25. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
[TBL] [Abstract][Full Text] [Related]
26. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
27. Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
Wawrzynczak EJ; Derbyshire EJ; Henry RV; Parnell GD; Smith A; Waibel R; Stahel RA
Br J Cancer; 1990 Sep; 62(3):410-4. PubMed ID: 2169852
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
Tsai LK; Pop LM; Liu X; Vitetta ES
Toxins (Basel); 2011 Apr; 3(4):409-19. PubMed ID: 22069716
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
[TBL] [Abstract][Full Text] [Related]
31. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P
Int J Cancer; 1995 Oct; 63(2):304-9. PubMed ID: 7591221
[TBL] [Abstract][Full Text] [Related]
32. Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.
Derbyshire EJ; Henry RV; Stahel RA; Wawrzynczak EJ
Br J Cancer; 1992 Sep; 66(3):444-51. PubMed ID: 1325825
[TBL] [Abstract][Full Text] [Related]
33. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
[TBL] [Abstract][Full Text] [Related]
34. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
[TBL] [Abstract][Full Text] [Related]
35. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
[TBL] [Abstract][Full Text] [Related]
36. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1994 Aug; 84(3):702-7. PubMed ID: 7519071
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
38. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; Eling WM; De Witte T
Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
[TBL] [Abstract][Full Text] [Related]
39. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
Myers DE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
[TBL] [Abstract][Full Text] [Related]
40. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
